PhosPrint

Advanced Technologies

PhosPrint is a developer of laser bioprinting systems and specialized regenerative medicine applications founded in 2019 as a Private Company in Greece, and is a spinoff of the Institute of Communication and Computer Systems of the National Technical University of Athens (ICCS/NTUA). The company developed an innovative dual beam laser bioprinting device adopted for on-site in vivo printing of cells during surgery. This is a highly disruptive technology, with numerous clinical applications that can transform healthcare and provide an innovative and permanent solution for patients. The 1st clinical application is in-vivo printing of urothelial cells in orthotopic neobladder surgery. To further optimize HW and SW and complete the first-in-human testing of the first application, PhosPrint received a €2mm Grant from the EIC Accelerator program that secures funding for 70% of the required budget of €2.8mm.

Phosprint is led by an exceptionally knowledgeable leadership team and employs 8 persons, including Biologists, Engineers and Laser experts. Dr Ioanna Zergioti, Co-Founder and Acting CEO, is the first scientist worldwide to publish laser bioprinting technology for solid phase DNA printing; Dr Apostolos Klinakis, Co-Founder and Clinical Director, has 25-year experience on cancer biology and mouse genetics. Ms. Maria Pallidou, MBA Co-Founder and CFO has 20+ years of experience in the Healthcare Industry. Dr Theo Kotseroglou, Board Member based in San Francisco is a medical devices business expert who has Co-founded and managed several MedTech companies. We have an exceptional group of Advisors to support and enhance our decision making, which comprises of two MD's and Professors at the Medical School, a Serial Entrepreneur and investor in healthcare, a Founder and Expert in Regenerative Medicine, and a seasoned MedTech executive.

We have a fully functional pre-industrial laser bioprinter (TRL-6) and protocols to isolate, expand and print cells during surgery. On going trials in pigs (n>10) have already produced very strong preclinical data, paving the way for a first in-humans clinical trial. The company has secured IP (4 patent families) and trade secrets (manufacturing know-how), protocols for cell isolation and expansion, and is currently in the process to establish a Quality management System (QMS) in compliance with EMA and FDA medical device regulations. In addition to the application of orthotopic neobladder with an estimated TAM of $1.3bn, the company has also successfully printed chondrocytes for cartilage repair (estimated TAM $1.6bn) with very promising initial results. Other applications of interest include blood vessel bioprinting and gynaecological indications.

Our main business stream is, upon the successful 1st in humans' trial, to become the 1st company operating in vivo printing for tissue repairing. The timeline for our first application which is bladder reconstruction is to enter the market by 2028 following EMA/FDA approval.

We are currently raising €0.8mm to match the remaining 30% from the Grant First funded project.
€0.4mm in 2024 and €0,4mm in 2025 in order to complete Phase I in humans. Following the successful outcome of the first in-humans trial by end of 2025, the company will complete the required clinical trials and certifications in order to commercialize its innovation by 2028. For the funding required to reach commercialization, the company already has a conditional commitment by the EIB to participate by 50% in the required financing, pending technical due diligence and participation of a lead investor. We anticipate that private investor funding for the commercialization phase will be at minimum an additional €2.5mm.

PhosPrint P.C.
Patriarchou Grigoriou E' & Neapoleos 27 Agia Paraskevi 15341, Athens, Greece
www.phosprint.eu, info@phosprint.eu